Search Within

Ross Levine

Formats
  1. Journal Article (386)
  2. Meeting Abstract (343)
  3. Editorial (14)
  4. Review (13)
  5. Research Letter (10)
  6. Book Section (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Whole (1)
Groups
  1. Adult Leukemia (774)
  2. Center for Hematologic Malignancies (774)
  3. Department of Medicine (774)
  4. Executive Committee, Center for Hematologic Malignancies (774)
  5. GSK Faculty (774)
  6. Hematologic Malignancies, Division of (774)

More Groups

People
  1. Omar Abdel-Wahab (166)
  2. Martin Tallman (131)
  3. Raajit Rampal (87)
  4. Eytan Stein (69)
  5. Maria Arcila (60)
  6. Jay Patel (52)

More People

Years
  1. 2025 (5)
  2. 2024 (32)
  3. 2023 (46)
  4. 2022 (41)
  5. 2021 (44)
  6. 2020 (58)

More Years

Publications
  1. Blood (289)
  2. Leukemia (34)
  3. Cancer Research (27)
  4. Haematologica (24)
  5. Blood Advances (21)
  6. Cancer Cell (21)

More Publications

Publishers
  1. American Society of Hematology (312)
  2. Nature Publishing Group (107)
  3. American Association for Cancer Research (67)
  4. Cell Press (47)
  5. Ferrata Storti Foundation (24)
  6. American Society of Clinical Oncology (22)

More Publishers

Results (774)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML)
    Meeting Abstract

    Zeidner, J. F.; Foster, M. C.; Johnson, M.; Huang, Y.; Swords, R. T.; Stein, E.; Foran, J. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Rai, S.; Stetka, J.; Usart, M.; Hao-Shen, H.; Park, Y.; Houston, R.; Martinez Benitez, A. R.; Wereski, M.; Guzzardi, E.; Persaud, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Entospletinib (ENTO) in combination with cytarabine (Ara-C) and daunorubicin (DNR) in newly diagnosed (ND) adult patients with NPM1-mutated and FLT3-ITD wild-type acute myeloid leukemia (AML) Is associated with good response and survival: A phase 2 sub-study of the beat AML master trial
    Meeting Abstract

    Borate, U.; Li, R.; Huang, Y.; Swords, R. T.; Traer, E.; Stein, E.; Foran, J. M.; Baer, M. R.; Duong, V. H.; Stock, W.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Mutational profile of children with myeloproliferative neoplasms
    Meeting Abstract

    Rutherford, K.; Farnoud, N.; Krishnan, A.; Rampal, R. K.; Levine, R. L.; Kucine, N.
    Blood (2022)

    Fulltext@MSK | Save
  • Escape from type II JAK2 inhibition in MPN depends on AXL/MAPK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J.; Ghosh, N.; Buczak, K.; Passweg, J.; Angelillo-Scherrer, A.; Dirnhofer, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia
    Meeting Abstract

    Robinson, T.; Bowman, R. L.; Persaud, S.; Liu, Y.; Gao, Q.; Zhang, J. P.; Sun, X.; Sciambi, A.; Llanso, A.; Famulare, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up
    Meeting Abstract

    Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Characteristics and prognostic effects of DNMT3A co-mutations
    Meeting Abstract

    Torabi, A.; Alonzo, T. A.; Othus, M.; Gerbing, R. B.; Wang, Y. C.; Ries, R. E.; Radich, J. P.; Appelbaum, F. R.; O'Dwyer, K.; Erba, H. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • JAK2(V617F) reversible activation shows an essential requirement for JAK2(V617F) in myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Dunbar, A.; Bowman, R. L.; Park, Y.; Izzo, F.; Myers, R. M.; Karzai, A.; Kim, W. J.; Maestre, I. F.; Waarts, M. R.; Nazir, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
    Guidelines

    Döhner, H.; Wei, A. H.; Appelbaum, F. R.; Craddock, C.; DiNardo, C. D.; Dombret, H.; Ebert, B. L.; Fenaux, P.; Godley, L. A.; Hasserjian, R. P.; more...
    Blood (2022)

    Fulltext@MSK | Save